Skip to main content
. 2024 Oct 1;15:8487. doi: 10.1038/s41467-024-52793-6

Fig. 9. Efficacy study using pancreatic BxPC−3 xenograft mouse model.

Fig. 9

a Comparison of paclitaxel administered intravenously once a week (QWK) at a dose of 12.5 mg/kg formulated in Cremophor® EL, ethanol and saline solution and Sol-paclitaxel 8vi dosed orally once every other day (QOD) at 25 mg/kg and 75 mg/kg (18 mg/kg and 55 mg/kg equivalent of paclitaxel dose respectively) formulated in saline solution. Drug was administered over 21-day period and then monitored for an additional 25 days with tumor volume measured twice a week. n = 8 mice per dose group. Data are presented as mean values +/− SD. Statistical significance was determined using an ordinary two-way ANOVA with Dunnett’s multiple comparison test. b Mouse weight plotted for the duration of the efficacy study (46 days). n = 8 mice per dose group. Data are presented as mean values +/− SD. ns = P > 0.05 when comparing treatment groups to vehicle. Statistical significance was determined using a mixed-effects analysis with Dunnett’s multiple comparison test. c Plasma and tumor concentrations of paclitaxel 6 and 24 h post-dose for each dose group. n = 2 mice per dose group. The bar chart shows individual and mean values. ND = not detectable. Mouse image created in BioRender. Smith, M. (2024) BioRender.com/d91z968.